Fig. 3
From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Subgroup analyses of progression-free survival. Osimertinib compared with gefitinib/erlotinib (A) or afatinib (B). A hazard ratio of less than one implies a lower risk of disease progression or death with osimertinib than with other EGFR-TKIs. Smoking status were not available for 2 patients in the gefitinib/erlotinib group, 2 patients in the afatinib group and 4 patients in the osimertinib group. Information was not available whether it was exon 19 deletion or L858R mutation for 1 patient in gefitinib/erlotinib group. There were no patient with stage III in afatinib group. CI, confidence interval